A phase 3 premarketing study of a combined contraceptive vaginal ring: A multi-centre, open label study on the efficacy, cycle control and safety of a contraceptive vaginal ring delivering a daily dose of 150 ìg of Nestorone ® and 15 ìg of Ethinyl oestradiol (150/15 NES/EE CVR).

Objectives of study: 

Healthy women, aged 18 to 38 years, wishing to use a non-oral contraceptive were participants in this year long study. There was a total of 13 cycles of ring use, for each cycle the participants wore the ring for 3 weeks in a row and then took it out for one week. Participants returned for follow-up during cycles 1, 3, 6, 9 and 13, with research staff maintaining regular contact inbetween scheduled visits.

Research status: 
Completed
Published articles: 

Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen.

Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen

Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen

Content Owner: 
Research